A kinetic model explains why shorter and less affine enzyme-recruiting oligonucleotides can be more potent by Pedersen, Lykke et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
A kinetic model explains why shorter and less affine enzyme-recruiting
oligonucleotides can be more potent
Pedersen, Lykke; Hagedorn, Peter H.; Lindholm, Marie Wickstrom; Lindow, Morten
Published in:
Molecular Therapy - Nucleic Acids
DOI:
10.1038/mtna.2013.72
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Pedersen, L., Hagedorn, P. H., Lindholm, M. W., & Lindow, M. (2014). A kinetic model explains why shorter and
less affine enzyme-recruiting oligonucleotides can be more potent. Molecular Therapy - Nucleic Acids, 3, [ e149].
https://doi.org/10.1038/mtna.2013.72
Download date: 03. Feb. 2020
Citation: Molecular Therapy—Nucleic Acids (2014) 3, e149; doi:10.1038/mtna.2013.72
© 2014 The American Society of Gene & Cell Therapy All rights reserved 2162-2531/14
www.nature.com/mtna
Introduction
Antisense oligonucleotides can be used to elicit RNase 
H-mediated cleavage and decay of target RNA.1 RNase H is 
a non-sequence-specific enzyme that recognizes RNA–DNA 
heteroduplexes and specifically cleaves the RNA strand.2 
Although the basic principle behind antisense was realized 
early,3 the binding affinity and pharmacokinetics of natural, 
unmodified, oligonucleotides were found to be insufficient 
for their use as systemic drugs.4 Therefore, central to the 
development of oligonucleotides for therapeutics lies efforts 
in medicinal chemistry to improve oligonucleotide stability, 
biodistribution, as well as RNA binding affinity. With the intro-
duction of high-affinity locked nucleic acids (LNAs),5,6 oligo-
nucleotides as short as 12nt in length have been reported to 
achieve sufficient binding affinity to potently silence their tar-
gets.7,8 Other types of modifications, such as 2′-O-methoxy-
ethyl and 2′-O-methyl,9 are also in use, although here 20nt 
are usually needed for sufficient binding affinity. Since none 
of these modifications allow recruitment of RNAse H, modi-
fied oligonucleotides are typically designed as gapmers, with 
high-affinity nucleotides in the flanks and a central gap of 
DNAs. A gapmer targeting apolipoprotein B (APOB), with five 
2′-O-methoxyethyls in the flanks and a central stretch of 10 
DNAs, was recently approved for the treatment of homozy-
gous familial hypercholesterolemia,10 and many others are 
in clinical development.4 Improving on the first-generation 
unmodified DNA oligonucleotides, it has been generally 
observed that high-affinity modifications improve the potency 
of the antisense drug candidate, with LNA and 2′-O-methoxy-
ethyl resulting in better potencies than 2′-O-methyl and 
unmodified bases.4,11 With such an apparent proportionality 
between the affinity and potency of antisense oligonucle-
otides, it would be expected that longer oligonucleotides 
tend to have higher potency than shorter ones, since more 
nucleotides increase affinity by allowing more hydrogen 
bonds and additional base stackings. But this simple expec-
tation is contradicted by experimental observations. To date, 
potency has been evaluated and reported for LNA-modified 
oligonucleotides between 12 and 20nt in length with between 
2 and 5 LNAs in the flanks. When stratifying by length it has 
been observed that shorter oligonucleotides targeting the 
same target site has increased potency compared with lon-
ger versions.7,8,11–13 So far, no mechanism for this seemingly 
counterintuitive increase in potency with decreases in affin-
ity has been demonstrated. Suggested explanations include 
variations in gapsize,7 less tendency to self-complementarity 
or improved pharmacokinetics of shorter oligonucleotides.12
In this paper, we ask if simple enzyme kinetics can account 
for these observations. Kinetic models have previously been 
successfully applied to explain and understand important 
actions of small RNAs or oligonucleotide-induced degra-
dation of messenger RNAs (mRNAs). In the work by Her-
schlag,14 the specificity of ribozymes and RNase H-recruiting 
oligonucleotides is investigated as a function of the length of 
their recognition sequence. As the sequence is made lon-
ger, the dissociation of mismatched duplexes is expected 
to become slower, and so the rate of cleavage for these 
mismatched RNAs will be increased relative to that of the 
intended target. This suggests the existence of an optimal 
length to achieve maximal discrimination between intended 
and unintended, mismatched, targets. Larsson et al.15 exam-
ined differences in the maximal achievable knockdown of 
mRNAs by small interfering RNA (siRNA) and microRNA. 
They demonstrate that mRNAs with high turnover rates 
are less efficaciously downregulated since the relative con-
tribution of an siRNA/microRNA to the degradation rate of 
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an already rapidly recycled mRNA is small. Finally, Roth,16 
when varying parameters of a kinetic model covering uptake, 
trafficking, and binding of oligonucleotides, noted that cellu-
lar uptake is less important for antisense effectiveness than 
intracellular trafficking, oligonucleotide-mRNA binding rate, 
and nuclease degradation. None of these models explicitly 
considered the binding of RNase H to the complex of target 
and oligonucleotide, and thereby missed the emergence of a 
target- and cell type-specific optimal binding affinity, which is 
our primary focus here.
Results
A kinetic model of oligonucleotide-mediated RNase H 
recruitment and degradation of mRNA
We aim to construct a simple quantitative model of oligonu-
cleotide action on a target RNAs. The model should be capa-
ble of addressing the observed relationship between affinity 
and potency. Since the experimental data available to us are 
from cell-based experiments, we do not consider pharmaco-
kinetical properties such as absorption, distribution, metab-
olism, and excretion. Unavoidable for this class of models, 
some parameters will be poorly known and dynamics will be 
simplified and effectively renormalized.17 If the model cap-
tures the salient features of the observations, however, it is 
a good indication that the mechanisms included will be of 
importance also in the more complex situation in vivo.
We model antisense silencing by RNase H-recruiting oligo-
nucleotides as a four-step process (Figure 1). First, the oligo-
nucleotide (O) hybridizes to the RNA target (T). Second, the 
RNase H enzyme (E) binds to the complex (OT). Third, the 
enzyme cleaves the target to yield a complex of oligonucle-
otide, cleaved target, and enzyme (OCE). And fourth, the OCE 
complex dissociates, releasing oligonucleotide and enzyme 
for a new cycle, and exposing the cleaved fragments to rapid 
degradation by exonucleases. This system is modeled as a set 
of ordinary differential equations (ODEs, see Methods).
Oligonucleotides developed for therapeutics often have 
a residence half-life in the tissue of interest on the order of 
weeks.18 Since we only model kinetic events on the order of 
hours, for simplicity, we assume that the total concentration 
of oligonucleotide, Ot, is constant. Similarly, the total amount 
of enzyme, Et, is assumed constant. The rate constants and 
initial concentrations of oligonucleotide and enzyme are set 
to values obtained from the literature (Table 1).
Time-resolved simulations of the model
When introducing a concentration of Ot = 0.1 nmol/l 
 (Figure 2a) or Ot = 100 nmol/l (Figure 2b) at time t = 0 
minutes, and simulating the model over time by numerical 
integration of the rate equations, we observe the expected 
behavior: the OT complex is formed first, closely followed by 
OTE. As RNA targets are degraded by the enzyme during 
repeated cycles, the concentrations of all compounds even-
tually reach a steady state, where natural as well as RNase 
H-mediated degradation of target is balanced by its constant 
production. As expected, a higher concentration of added 
oligonucleotide (Figure 2b) results in larger reduction of tar-
get than a lower concentration (Figure 2a). Steady state is 
reached after ~1–2 hours as in Figure 2a,b. Experimentally, 
target levels are often measured after several hours or even 
days. Therefore, we assume steady state in the following.
Model-simulated dose–response curve
In practice, after addition of oligonucleotide to cells or tis-
sue, target silencing is quantified by measurement of the 
target concentration and compared with a control situation 
without the oligonucleotide. In untreated cells, the steady-
state concentration of target is [ ] =T v kprod T→∅ . Since a 
transcript is translatable even when oligonucleotides are 
bound to it,19 the total target concentration [T] + [OT] + [OTE] 
is the relevant quantity for evaluation of functional knock-
down. This is also what is measured by quantitative reverse 
Figure 1 Schematic of the modeled reactions. Initially the 
oligonucleotide (O) binds to the target (T) and forms the OT complex, 
which recruits the enzyme (E). Within the OTE complex, the target is 
cleaved (C) to form OCE. The enzyme and then the oligonucleotide 
dissociates from the cleaved target to enter a new round of catalysis. 
The target has a constant production rate denoted by νprod, and a 
basal oligonucleotide- and RNase H-independent degradation rate, 
kT→∅. Here, ∅ denotes completely degraded target. The dissociation 
rate of enzyme from OT and OC is assumed to be the same.
O
OT
OTE
T ØkT→Øνprod
Ø
OCE
OC
E
Ø
kOT→O+TkO+T→OT
kOTE→OT+E kOTE→OT+E
kOTE→OCE
kOT+E→OTE
kOC→O+C
kT→Ø
kT→Ø
Table 1 Default values for the parameter-space of the model taken from the 
literature
Parameter Description
Default 
value Unit Reference
Et Total RNase H  
concentration
1 nmol/l 35
Ot Total oligonucleotide 
 concentration
Varies nmol/l
νprod Production of target 0.2 nmol/l/min 36
kT→∅ Degradation of target 0.04 min−1 37
KdOT Dissociation constant of 
the OT complex
0.3 nmol/l 38
kO T OT+ → Association rate of the OT 
complex
0.2 (nmol/l min)−1 38
KdOTE Dissociation constant of 
the OTE complex
70 nmol/l 35
kOT E OTE+ → Association rate of the 
OTE complex
5 (nmol/l min)−1 35
kOTE OCE→ Rate of target cleavage by 
RNase H
8 min−1 35
α Ratio between 
 dissociation rates: 
k kOT O T OC O C→ + → + ≤ 1
0.1
Concentrations are measured in nmol/l and time in minutes.
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transcriptase–polymerase chain reaction (PCR). We use 
the model to calculate the steady-state ratio (T
rel) of target 
levels in treated versus untreated (or control treated) cells 
as a function of Ot. This yields a dose–response curve (Fig-
ure 2c), with an efficacy (the maximum decrease in T
rel) and 
potency, dependent on the choice of model parameter values 
(Supplementary  Figures S1 and S2). Potency is defined as 
the inverse of the half-maximal effect concentration, EC50, 
which in mathematical terms is defined as:
EC Efficacy50 t rel rel,min= = 2
O T T+


 (1)
with T TOrel,min t rel= →∞lim . According to the model, the efficacy 
of an oligonucleotide can be increased, by increasing the rate 
by which the OT complex recruits RNase H and the rate by 
which RNase H cleaves the target (Supplementary Figure 
S2). However, changing the formation rate of the OT complex 
has no effect on the efficacy. In general, a high concentration 
of RNase H improves both the efficacy and the potency, and 
a low target production and a low basal (non-oligonucleotide 
mediated) target degradation rate also improves efficacy and 
potency. Therefore, cells with high concentrations of RNase 
H and targets with low production and degradation rates are 
preferred for antisense oligonucleotides therapeutics.
The kinetic model predicts the existence of an optimal 
binding affinity
Examining EC50 as a function of the binding affinity between 
the oligonucleotide and the target, we see that EC50 decreases 
with increasing affinity to a certain point where the effect of 
increased affinity reaches a plateau (Figure 2d, dashed line). 
Here, the affinity is defined as the inverse of the dissociation 
constant between the oligonucleotide and the target (KdOT), 
which is in turn defined by the ratio between the dissociation 
and association rate of OT, i.e., K k kdOT OT O T O T OT= → + + → . 
In principle, KdOT can change if either of the association or 
dissociation rates are changed. The association rate can be 
interpreted as the frequency by which a collision between the 
oligonucleotide and the target site will be aligned sterically 
in such a way as to allow formation of base pairs and thus 
binding. For oligonucleotides, this collision frequency is pri-
marily limited by the accessibility of the RNA, i.e., the second-
ary structure of the targeted RNA.20–23 The dissociation rate is 
interpreted as how often the energy of the thermal vibrations 
will be able to overcome the free energy of hybridization and 
Figure 2 Model solutions and identification of an optimal binding affinity. (a,b) Time-resolved simulation of the relative concentrations of key 
species in the reaction scheme from Figure 1. Oligonucleotide (O) is added at time t = 0 minute at a concentration of (a) 0.1 and (b) 100 
nmol/l. (c) The relative total target concentration (T
rel) as a function of total oligonucleotide concentration at typical parameter settings (Table 1). 
Dashed lines indicate efficacy (horizontal) and half-maximal effect concentration (EC50) (vertical). Arrows indicate the total oligonucleotide 
concentrations used in (a) and (b). (d) The EC50 as a function of the dissociation constant for the OT complex. A low dissociation constant 
between the oligonucleotide and the target (KdOT) corresponds to a high binding affinity. Dashed line: no coupling between kOT O T→ +  and kOC O C→ + . Solid line: k kOT O T OC O C→ + → +⋅= α . (e–g) Experimental knockdown as a function of calculated ΔG°: (e) for 21 oligonucleotides at 2 
nmol/l targeted against the luciferase firefly gene,7 (f) for 14 oligonucleotides at 3 nmol/l targeted against the glucocorticoid receptor,13 and 
(g) for 23 oligonucleotides at 1 nmol/l targeted against apolipoprotein B (APOB), (h) 4 oligonucleotides at 0.06 μmol/l and 1.5 μmol/l against 
PCSK9. Legend indicates oligonucleotide lengths. Target messenger RNA concentrations are measured by (e) luciferase assay and (f,g,h) 
quantitative reverse transcriptase–polymerase chain reaction. Dots are experimental data and gray lines are a least squares fit to a second-
order polynomial with P values and vertex for the fit in each of the panels e–h.
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allow dissociation. In practice, affinity is altered by adjusting 
the number of base pairs (by shortening or lengthening the 
oligonucleotide) or by adjusting the strength of each base pair 
(by adding or removing high-affinity modifications). Hence, we 
model affinity changes by modulating the dissociation rate, 
kOT O T→ + , while keeping the association rate, kO T OT+ → , con-
stant. The experimental range of KdOT-values is taken from the 
literature.16
Next, we reasoned that there is an important coupling 
between the rate at which an oligonucleotide dissociates 
from an uncleaved target and the rate at which it leaves the 
cleaved target. After the enzyme hydrolyzes the phosphodi-
ester backbone of the RNA target, the dissociation becomes 
a two-step process: either the left or right end leaves first 
 (Figure 3). The slowest of these processes will be rate-limiting 
for the recycling of free oligonucleotide (denoted as kOC O C→ + ). 
If the dissociation rate from the intact target (kOT O T→ + ) is 
decreased (e.g., due to increased affinity), kOC O C→ +  must 
also be decreased. Moreover, since after cleavage, there will 
be fewer base pairs (and thus fewer hydrogen bonds and 
stacking interactions) to break than when dissociating from 
an intact target, k kOC O C OT O T→ + → +< . This is included in the 
model by the simple, linear relation k kOC O C OT O T→ + → += /α, 
where 0 < α< 1. A high value of α models a case where the 
oligonucleotide leaves the cleaved target at a rate close to 
the rate at which it dissociates from the intact target. Intrigu-
ingly, irrespective of the actual value of α, the introduction of 
this coupling between kOT O T→ +  and kOC O C→ +  reveals a rela-
tionship between EC50 and affinity (Figure 2d, solid line), 
where there is an optimal affinity beyond which additional 
added affinity is detrimental to potency. Intuitively phrased, 
the higher the affinity toward the uncleaved target, the higher 
the affinity will also be to either parts of the cleaved target. 
And a high affinity toward the cleaved target results in a slow 
release of enzyme and oligonucleotide, which stalls the cata-
lytic cycle and therefore reduces potency.
The ODEs behind the model (Eqs. 1–7) allow both deter-
ministic, time-resolved, simulations (Figure 2a,b) and deri-
vation of algebraic solutions. We also explored stochastic 
simulations24 of the ODEs. This reproduced the existence 
of an optimal affinity (Supplementary Figures S3 and S4), 
supporting the deterministic solution to the ODEs.
Experimental support for an optimal binding affinity
To investigate if the model-predicted existence of an optimal 
affinity could be confirmed by experiments, we reanalyzed 
data from two published studies evaluating the ability of dif-
ferent oligonucleotides to reduce luciferase (LUC) mRNA in 
HeLa cells7 and glucocorticoid receptor (GR) mRNA in Hep3B 
cells,13 respectively (Supplementary Material S1 for oligo-
nucleotide data and Supplementary Material S2 for mRNA 
sequences). Using a validated nearest-neighbor model for 
LNA-modified oligonucleotide-binding to RNA (see Methods), 
we calculated standard free energies of binding at 37 °C, ΔG°, 
for those oligonucleotides in the two studies where both target 
knockdown efficiency and temperatures of melting, T
m
 (needed 
for the validation), were available. Plotting ΔG° values calcu-
lated in this manner against the realized target knockdown in 
each study (Figure 2e,f) confirms the model’s prediction of a 
region of optimal affinity (Figure 2d). We note that the model 
predictions of EC50 as a function of KdOT closely resembles 
a parabola over the experimentally observed affinity range 
(Figure 2d and Supplementary Figure S5). To estimate an 
optimal ΔG° from the data we therefore fit a second-order poly-
nomial by least squares (gray lines in Figure 2e,f). As seen 
in Figure 2e,f, the optimal ΔG° is estimated to −23 and −19 
kcal/mol, respectively. Furthermore, to confirm the presence 
of an affinity optimum also for a well-established antisense 
target of clinical importance,10 and independently of the length 
of the oligonucleotides, we synthesized and evaluated a set 
of compounds consisting of four 12-mers, two 13-mers, and 
seventeen 14-mers complementary to the APOB mRNA. The 
23 oligonucleotides cover a broad range of predicted affinities. 
The ability of all the oligonucleotides to reduce the levels of 
APOB mRNA in HuH-7 cells were quantified by quantitative 
reverse transcriptase–PCR. Similar to the historic published 
data (Figure 2e,f), this experiment also showed that oligo-
nucleotides with a calculated ΔG° in a mid-range tended to 
have a better effect on APOB, than oligonucleotides on either 
side of this range (Figure 2g), with an optimal ΔG° around 
−18 kcal/mol. Moreover, in all three studies (Figure 2e–g), oli-
gonucleotides of the same length in isolation also display the 
affinity optimum; the 16-mers in Figure 2g and the 14-mers 
in Figure 2f and Figure 2g. From this, we conclude that the 
observed optimum is not caused by length per se, but rather 
by affinity, as indeed predicted by the model.
Finally, in both the LUC and GR transcripts, oligonucleotides 
are targeted to three different binding regions (starting posi-
tions in the transcripts are listed in Supplementary Material 
S1 for all oligonucleotides). Which region a given oligonucle-
otide is targeted to is indicated in Figure 2e,f by either a gray 
hexagon, triangle, or square behind the point representing that 
oligonucleotide. This allows us to investigate whether the bind-
ing region can influence the position of the affinity optimum. In 
 Figure 2e, four oligonucleotides against LUC region A (hexa-
gons) display decreased knockdown efficiency as binding 
affinity increases (negative slope). In contrast, four oligonucle-
otides against LUC target region B (triangles) display increased 
knockdown efficiency as binding affinity increases (positive 
slope). The 13 oligonucleotides against LUC target region C 
Figure 3 Schematic drawing of target cleavage illustrating the 
rationale for introducing the coupling k kOT O T OC O C→ + → +⋅= – . 
Upon enzyme (E, RNase H) binding to the OT complex the target is 
cleaved at a rate kOTE OCE→ . After cleavage, the right and left parts of 
the cleaved target will dissociate from the oligonucleotide at (faster) 
rates k
right and kleft, respectively.
Oligo
Target
RNAse H
OR
Cleaved
target
kOTE→OCE
kleft
kOC→O+C = min(kleft, kright) > kOT→O+T
kright
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(squares), span a broader range of affinities and by them-
selves trace out the parabolic relation. Especially for ΔG° < 25 
kcal/mol (Figure 2e), it seems that the different binding regions 
explain some of the variation in the data. In Figure 2f, both 
oligonucleotides targeted to binding region A and C by them-
selves trace out the parabolic relation, and there are no obvi-
ous systematic variation between binding regions. In  Figure 
2g, the oligonucleotides are not focused on specific regions 
but tiled across the transcript (Supplementary Material 
S1). This may explain the larger variation around the fitted 
curve for this data set, which is supported in the model, since 
differences in accessibility of the target region can be captured 
as differences in kO T OT+ → , which will affect KdOT. To confirm that 
a single target region is sufficient to establish the parabolic 
relation, we designed four oligonucleotides against the same 
binding region in PCSK9 and evaluated reduction in transcript 
levels at two doses by quantitative reverse transcriptase–PCR. 
As seen in Figure 2h, these four oligonucleotides by them-
selves demonstrate the optimal  affinity, especially for the low 
dose, even though the span of affinities, −17 to −21 kcal/mol, is 
relatively narrow (compare  Figure 2h with Figure 2e–g).
The optimal binding affinity is dependent on turnover 
rates and RNase H levels
Although the experimental data are relatively sparse, it 
appears as if the optimal affinity may be different between 
studies (Figure 2e–g). To investigate this further, we exam-
ined the model with regard to factors, which are likely to be 
different between different targets or different cellular con-
texts (Figure 4). A higher total RNase H concentration (Et) 
decreases the optimal affinity and increases the potency 
(Figure 4a). On the other hand, a lower Et value increases 
the optimal affinity and decreases the potency. A fast turn-
over of the target, i.e., high rates of νprod and kT→∅, decreases 
the potency (Figure 4c,d). However, a slow target produc-
tion increases the optimal affinity, whereas a slow basal tar-
get degradation decreases it. This is similar to the findings 
of microRNAs and siRNAs, where it has been shown that 
mRNAs with a high turnover rate are more resistant to micro 
RNA and siRNA silencing.15 In summary, the model predicts 
that the optimal affinity is influenced by the target and the 
context in which the reaction takes place.
Discussion
In vivo a multiplicity of factors influences the potency of 
an oligonucleotide. These include stability, protein bind-
ing, excretion, metabolism, uptake and diffusion into tis-
sue, and uptake into cells and trafficking inside cells. The 
simple kinetic model presented here, however, provides a 
sufficient explanation for the experimental observation of 
increased potency with decreased length.7,13 Our study 
suggests that for a given target (with its associated basal 
turnover rates) and a given cell type (with its RNase H con-
centration), there is an optimal affinity. With the important 
coupling between the dissociation rates of the oligonucle-
otide from intact and cleaved target (kOT O T→ +  and kOC O C→ + ), 
the model predicts, and the experimental data confirm 
that oligonucleotides deviating, in either direction, from 
the optimum tend to have lower potency. It is well known, 
and follows almost intuitively from basic principles (and our 
model) that oligonucleotides with too low affinity will have 
low potency. They therefore have to be dosed at very high 
and saturating amounts to bind an appreciable fraction of 
the target transcripts, and oligonucleotide recycling is not 
limiting (right-hand side of Figure 2d). That oligonucle-
otides with too high affinity may also have reduced potency, 
and that it can be explained by limited recycling, has to 
our knowledge not been appreciated before (left-hand side 
of Figure 2d). This insight has practical implications when 
designing oligonucleotide libraries for drug discovery.
Since the modeling shows that the position of the affinity 
optimum is parameter dependent (Figure 4), our recom-
mendation for oligonucleotide drug discovery is to initially 
design a set of oligonucleotides with affinities broadly cov-
ering the expected optimum. This allows the optimal affin-
ity for that target and cellular context to be identified, as 
demonstrated in Figure 2e–h. Subsequent sets of oligo-
nucleotides can then be designed with binding affinities as 
close to this experimentally identified optimum as possible, 
keeping in mind that different binding regions may shift 
the position of the optimum to some extent (Figure 2e–h). 
This may be due to differences in accessibility, which we 
speculate could influence KdOT, although measurements of 
target structure related to observed optimal affinities will 
be needed to confirm this relation. We routinely synthesize 
oligonucleotides with a range of calculated ΔG° values from 
−10 to −30 kcal/mol, and usually find the optimum between 
−16 and −22 kcal/mol.
While 2′ modifications to oligonucleotides are known to 
increase affinity, other modifications decrease the affinity, 
e.g., phosphorothioate backbone substitutions.25 Previously, 
we considered the use of affinity decreasing modifications as 
a tradeoff between the loss of affinity and the gain in other 
beneficial properties (e.g., increased plasma protein binding 
and cellular uptake). However, our present results indicate 
that in the context of a highly affine oligonucleotide, using 
affinity lowering chemistry will be advantageous, since a 
conjugate or other modification could move a too affine com-
pound back into the affinity optimum.
Although this study has focused entirely on RNase 
H-recruiting oligonucleotides, the reaction scheme may be 
similar for siRNAs recruiting RNA induced silencing complex, 
suggesting that a similar phenomena could be present in this 
system. Although it is also possible that other mechanisms 
(e.g., RNA induced silencing complexs preference for certain 
bases at certain positions) could have a more dominating 
effect on the potency.
The kinetic model is deliberately limited to contain only 
the reactions central to enzyme-mediated cleavage of RNA. 
This is important to avoid inflating the number of parameters. 
However, additional insights could possibly be gained by 
expanding the model. Possibilities include adding reactions 
for oligo-dimerization and self-folding (both of which can be 
reasonably predicted computationally)26 or even investigate 
the effect of lower affinity unintended targets that could theo-
retically deplete the amount of oligonucleotide.27 The source 
code for our model is downloadable under a Creative Com-
mons License that enables others to easily explore these or 
other extensions.
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In summary, we provide a simple theoretical explanation 
for the until now unexplained observation that long (and 
very affine) oligonucleotides tend to be less potent than 
shorter (and less affine) versions. We show that the effect 
is due to affinity rather than length and provide an enzyme 
kinetic model that explains the observation, without invoking 
additional complexities such as cellular uptake and protein 
binding. In our opinion, this demonstrates how examination 
of basic physical principles can inform one of the most fun-
damental processes of oligonucleotide based therapeutics: 
how to design the sequence and its modifications.
Materials and methods
Equations governing antisense oligonucleotide-mediated 
target degradation. The kinetic model consists of seven 
ODEs of the seven variables: free target (T), free oligo-
nucleotide (O), free RNase H (E), complex of oligonucle-
otide and target (OT), complex of oligonucleotide, target, 
and RNase H (OTE), complex of cleaved target, oligonucle-
otide, and RNase H (OCE), and complex of cleaved target 
and oligonucleotide (OC):
d T
dt
v k T k T O k OT[ ] = [ ] [ ][ ] [ ]prod T O T OT OT O T− − +→∅ + → → +
 
(2)
d O
dt
k OT k O T
k OC k OT OT
[ ]
= [ ] [ ][ ]
[ ] ([ ] [
OT O T O T OT
OC O C T
→ + + →
→ + →∅
−
+ + + E ])
 
(3)
d E
dt
k OTE k E OT
k OTE OCE
[ ]
= [ ] [ ][ ]
([ ] [ ])
T OT E OTE
OTE OT E
→∅ + →
→ +
−
+ +
 
(4)
d OT
dt
k O T k OT
k OT E k
[ ]
= [ ][ ] [ ]
[ ][ ]
O T OT OT O T
OT E OTE OTE OT
+ → → +
+ → →
−
− + + →∅−E T[ ] [ ]OTE k OT
 
(5)
d OTE
dt
k E OT k OTE
k k O
[ ]
= [ ][ ] [ ]
( )[
OT E OTE OTE OT E
T OTE OCE
+ → → +
→∅ →
−
− + TE ]
 
(6)
d OCE
dt
k OTE k OCE[ ] = [ ] [ ]OTE OCE OTE OT E→ → +−
 
(7)
d OC
dt
k OCE k OC[ ] = [ ] [ ]OTE OT E OC O C→ + → +−
 
(8)
Complex formation and breaking are denoted by rate con-
stants k with subscripts. The target production rate is denoted 
by νprod and the degradation rate by kT→∅. The parameter val-
ues are listed in Table 1.
Simulations. An R implementation of the FORTRAN ODE 
solver vode28 is used to solve the system of seven ODEs of 
the model. This solver is a variable-coefficient method where 
the step-size is calculated at each time point. All calculations 
and simulations were performed in R (v.3.0.0: R Core Team 
(2013). R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria. 
URL http://www.R-project.org/) and is described in our ASO-
models package obtainable from https://github.com/lykkep/
ASOmodel, which also contains all data from this manuscript.
Oligonucleotides. LNA-modified antisense oligonucleotides 
were synthesized with complete phosphorothioate backbones 
using standard phosphoramidite protocols on an Expedite 
8900 synthesizer with a Multiple Oligonucleotide Synthe-
sis System unit (ABI, Foster City, CA). The oligonucleotides 
were purified by reverse-phase high-performance liquid 
chromatography. Liquid chromatography-mass spectrometry 
(reverse phase and electrospray ionization-mass spectrom-
etry) were used to verify compound identity and purity. For the 
full sequences see Supplementary Material S1.
In vitro activity screening of oligonucleotides. For APOB target-
ing oligonucleotides, human hepatocellular carcinoma, HuH-7, 
cells were transfected 24 hours after seeding with oligonucle-
otides at final concentration of 1 nmol/l, using lipofectamine 
2000 (Invitrogen, Carlsbad, CA), according to the manufactur-
ers instructions. Cells were harvested 24 hours after transfec-
tion and total RNA isolated using the RNeasy mini kit  (Qiagen, 
Hilden, Germany). The PCSK9 targeting oligonucleotides were 
Figure 4 The optimal model-predicted affinity is dependent on the 
physiological parameters. The half-maximal effect concentration 
(EC50) is plotted against the binding affinity, quantified by dissociation 
constant between the oligonucleotide and the target (KdOT), while 
varying (a) the total RNase H concentration, Et, (b) the coupling 
constant, α, (c) the target production, νprod, (d) the target degradation, kT→∅, (e) the dissociation constant for the OTE complex, KdOTE, and (f) the rate of target cleavage, kOTE OCE→ .
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taken up unassisted in the prostate cancer cell line 15PC3, 24 
hours after seeding, at final concentrations of 0.06 or 1.5 μmol/l. 
Cells were harvested after 3 days of uncubation with oligonucle-
otide and total RNA isolated using the RNeasy mini kit. In both 
screens, transcript levels were quantified using TaqMan assays 
(Applied Biosystems, Foster City, CA). The reverse transcrip-
tion reaction was carried out with random decamers, 0.5 mg 
total RNA and the M-MLV RT enzyme (Ambion, Naerum, Den-
mark) according to protocol. Dependent on expression level, 
first-strand complementary DNA was subsequently diluted five 
times in nuclease-free water before addition to the reverse tran-
scriptase–PCR reaction mixture. The Applied Biosystems 7500 
real-time PCR instrument was used for amplification. Transcript 
levels were normalized to glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and presented as percentage-change 
relative to average levels in mock-treated controls. Knockdown 
data are available in Supplementary Material S1.
From melting temperatures to a nearest-neighbor model for 
binding affinity. The melting temperature is defined as the tem-
perature at which half of the oligonucleotides are duplexed 
with target RNA, and is an often-used experimental measure 
of duplex stability, although not strictly proportional to binding 
affinity at physiological conditions.29 Instead, the standard free 
energy of binding, ΔG° at 37 °C, is a more physiologically rel-
evant representation of binding affinity, since KdOT is logarithmi-
cally proportional to ΔG°.30 Also, calorimetric measurement of 
T
m
 by thermal denaturation is affected by oligonucleotide con-
centration and presence of cations in the buffer,29 conditions 
which often differ between studies.7,13 To allow comparisons 
between studies reporting T
m
 values, and in particular to be 
able to replace T
m
 with ΔG°, we therefore constructed a near-
est-neighbor model with thermodynamic parameters taken 
from the literature.31–33 To validate the model, we used it to cal-
culate T
m
 for oligonucleotides from the two studies with historic 
data  (Figure 2e,f), where both knockdown data and experi-
mentally measured T
m
 values were available. The residual 
standard error between experimental and calculated T
m
 is ±2.6 
°C for the LUC targeting oligonucleotides7 and ±3.5 °C13 for the 
GR targeting oligonucleotides13 (Supplementary Material S1). 
This is comparable with reported accuracies for nearest-neigh-
bor models,33 confirming the validity of the nearest-neighbor 
model-based calculation for these oligonucleotides. Impor-
tantly, the nearest-neighbor model also allows calculation of 
ΔG°, based on the same thermodynamic parameters.34
Supplementary material
Figure S1. Dose–response curves for different values of Et, 
α, νprod, kT→∅, KdOT, kO+T OT→ , KdOTE, kOT+E = OTE, and kOTE OCE→  (top,left to bottom,right).
Figure S2. Efficacy and EC50 is plotted as functions of pa-
rameter values for Etot, KdOTE, νprod, α, kO+T OT→ , kOT+E = OTE, 
kT→∅, kOTE OCE→ .
Figure S3. The time-trace for the relative total target level 
when the model is simulated stochastically.
Figure S4. Left: Dose–response curves for various values 
of kOT O+T→  (compare to Supplementary Figure S1, middle). 
Right: EC50 as a function of kOT O+T→ . A high value of kOT O+T→  
corresponds to a low affinity.
Figure S5. EC50 as a function of KdOT is fitted on a log-log 
scale to a parabola.
Material S1. Oligonucleotide data.
Material S2. mRNA sequences.
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